LucyRx Expands Executive Team
BETHESDA, Md.--(BUSINESS WIRE)-- LucyRx, a next-generation pharmacy benefits manager (PBM) committed to simplifying and improving access to prescription care, recently added four healthcare industry veterans to expand core operations, including legal, sales and government programs as the company continues its rapid growth nationwide.
With patient-focused and fairly priced pharmacy benefits in high demand, LucyRx has grown quickly, now covering more than one million members with 1,200 health plan clients across the U.S.
Share
With patient-focused and fairly priced pharmacy benefits in high demand, LucyRx has grown quickly, now covering more than one million members with 1,200 health plan clients across the U.S.
These healthcare veterans add valuable depth to support the company's growth—as more organizations choose its member-centered, technology-driven approach to prescription benefits.
Paul Brown, Chief Legal Officer and General Counsel, will oversee the company's legal strategy, compliance and risk management. Paul brings extensive experience in regulatory compliance, commercial transactions and M&A execution and integration from prior roles at Kaufman Hall (a Vizient company) and UL Solutions.
Michael McCarrell, Chief Operating Officer, will lead all core operational areas including customer service, claims administration and clinical operations. Michael brings over 25 years of healthcare leadership experience, most recently as President and COO of CPS Solutions, where he led the nation's largest hospital pharmacy services provider.
Crescent Moore, Senior Vice President of Government Programs, will lead LucyRx's expansion into Medicare and other government-sponsored markets. Crescent brings nearly two decades of leadership in Medicare Part D and clinical strategy, most recently as Director Part D/Pharmacy at BluePeak Advisors.
Cody Field, Senior Vice President of Employer Sales, joins LucyRx with a strong background in clinical care, account management, and business development. Most recently at Marsh McLennan, Cody brings a patient-first mindset and deep healthcare experience that will further strengthen LucyRx's partnerships with employers nationwide.
'Each of these leaders brings significant experience to ensure LucyRx is the most innovative, highest performing, patient-centered prescription benefit provider in the industry,' said David Blair, CEO of LucyRx. 'With Mike, Paul, Crescent and Cody on board, we're well positioned to bring our vision to life: prescription care, brilliantly reimagined.'
About LucyRx
LucyRx is an independent, next-generation pharmacy benefit manager (PBM) redefining prescription care. Fueled by innovation and decades of leadership experience, LucyRx delivers better outcomes through its integrated specialty network, formulary marketplace, and next-day home delivery solutions. Powered by its proprietary AI platform, LucyIQ™, the company provides real-time insights that support evidence-based clinical decisions, clear pricing, and exceptional service from U.S.-based pharmacy technicians. Partnering with more than 60,000 pharmacies, LucyRx serves over 1,200 clients nationwide.
This is prescription care, brilliantly reimagined.
Learn more at LucyRx.com.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Wire
an hour ago
- Business Wire
SOLVE FSHD and Modalis Announce Strategic Collaboration to Develop an Innovative CRISPR-Based Epigenome Editing Treatment for Facioscapulohumeral Muscular Dystrophy
VANCOUVER, British Columbia & TOKYO & WALTHAM, Mass.--(BUSINESS WIRE)-- SOLVE FSHD, a venture philanthropy organization dedicated to accelerating treatments for facioscapulohumeral muscular dystrophy (FSHD), and Modalis Therapeutics Corporation (TSE 4883; 'Modalis'), a CRISPR-based epigenome editing therapeutics company focused on rare genetic diseases, today announced a strategic collaboration to develop an innovative therapy for FSHD, a debilitating muscular disorder affecting approximately 1 million individuals worldwide. The novel therapy leverages Modalis's proprietary CRISPR-GNDM ® (Guide Nucleotide-Directed Modulation) technology, which can dynamically modulate gene expression without introducing double-strand DNA breaks. SOLVE FSHD will provide strategic funding to support the development of Modalis's MDL-103 program. MDL-103 is an innovative therapeutic solution that continuously suppresses the expression of the DUX4 gene, the toxic disease-causing gene for FSHD, which becomes abnormally activated due to epigenetic changes in the D4Z4 repeat region on chromosome 4. MDL-103 is designed to have durable activity over long periods of time under the control of a strong, muscle-specific promoter, and is delivered to the muscles of patients using a muscle-tropic AAV delivery system. Modalis's CRISPR-GNDM ® technology has the potential to transform the treatment of FSHD by epigenetically silencing the expression of DUX4. 'SOLVE FSHD is pleased to partner with Modalis and to add them to our diverse portfolio of collaborators that are advancing potential therapies for FSHD,' stated Eva Chin, Executive Director of SOLVE FSHD. 'SOLVE FSHD identified Modalis as a company committed to finding a cure for this debilitating condition. We were impressed by their unique approach to targeting the epigenetic cause of FSHD, using a platform technology that has shown promise in other neuromuscular diseases. We believe that the support from SOLVE FSHD will allow Modalis to accelerate the advancement of MDL-103 into clinical trials.' 'We are delighted to be working in partnership with SOLVE FSHD and greatly appreciate the invaluable support for the development of MDL-103,' said Haru Morita, CEO of Modalis. 'This strategic collaboration is a strong validation of Modalis's CRISPR-GNDM ® technology and our MDL-103 program. As a pioneer in this technology, we have demonstrated promising long-term drug efficacy in mouse models, shown durable target engagement and safety in non-human primates, and exhibited excellent biodistribution in neuromuscular disorders. We believe that MDL-103, which incorporates CRISPR-GNDM ® technology with a muscle tropic AAV delivery system, has significant potential as a breakthrough treatment for FSHD.' About SOLVE FSHD SOLVE FSHD is a venture philanthropic organization established to catalyze innovation and accelerate key research in finding a cure for FSHD. Established by renowned Canadian entrepreneur and philanthropist, Chip Wilson, the Wilson family has committed $100 million to kick-start funding into projects that support the organizations' mission to solve FSHD by 2027. The goal of SOLVE FSHD is to find a solution that can slow down or stop muscle degeneration, increase muscle regeneration and strength, and improve the quality of life for those living with FSHD, visit Modalis was founded in 2016 and conducts research and development activities in Massachusetts, USA. Modalis is a pioneering leader in the field of epigenetic medicine. Modalis develops therapeutics for patients suffering from serious genetic disorders such as neuromuscular diseases, CNS diseases, and cardiomyopathies. Modalis's proprietary CRISPR-GNDM ® technology is capable of specifically up or down modulating the expression of disease-relevant genes without introducing double-strand DNA breaks. For more information, visit
Yahoo
4 hours ago
- Yahoo
Rich Paul believes when it comes to competition, ‘there is none'
The post Rich Paul believes when it comes to competition, 'there is none' appeared first on ClutchPoints. Rich Paul didn't just rise in the world of sports representation, he redefined it. The Klutch Sports Group founder and longtime LeBron James confidant is the latest high-profile expert to partner with MasterClass, where he'll offer an inside look at what it takes to dominate an industry from the ground up, per AthlonSports. The course drops June 9, and in a promotional clip released Friday, Paul makes his philosophy crystal clear when asked who his biggest competition is. His answer: 'There is none.' That statement isn't just bravado. It reflects a relentless work ethic forged in Cleveland and sharpened through over two decades of navigating NBA power structures. From a chance encounter with James at an airport (where Paul caught his attention with a vintage Warren Moon jersey) to managing the careers of stars like Anthony Davis, Draymond Green, Lonzo Ball, and Bronny James, Paul has built a legacy rooted in instinct, trust, and grit. Advertisement MasterClass, the digital platform that fuses documentary-style filmmaking with high-level education, is the perfect stage for someone like Paul. It's where curiosity meets expertise. Names like Sara Blakely, Martha Stewart, and Serena Williams don't just inspire — they instruct. For $10 a month, subscribers gain direct access to elite voices. Now, Rich Paul joins that lineup. Legacy in Motion Since launching Klutch Sports in 2012 after leaving Creative Artists Agency, Paul has proven time and again that knowing your craft means knowing your worth. He's become a symbol of power off the court, helping reshape player empowerment in professional sports. In 2019, Sports Illustrated dubbed him 'The King Maker.' That same year, United Talent Agency (UTA) invested in Klutch and appointed Paul as co-head of its entire sports division. He didn't stop there. By 2020, Paul had launched Klutch Conversations to promote financial literacy among young people. He also joined UTA's board of directors and was named GQ's 'Power Broker of the Year,' continuing a streak of accolades that highlight the impact he's made beyond the headlines. Advertisement With his MasterClass, Paul isn't just teaching deals or contracts. He's offering a blueprint — not for how to follow, but how to lead. Because in his eyes, there's no race when you set the pace. Related: WWE news: Ric Flair confirms second cancer diagnosis in 3 years Related: Livvy Dunne reveals pitch she 'taught' boyfriend Paul Skenes
CBS News
5 hours ago
- CBS News
Kevin Hassett says if Senate finds Medicare abuse, then "we would look at it" in Trump bill
Kevin Hassett says if Senate finds Medicare abuse, then "we would look at it" in Trump bill White House National Economic Council director Kevin Hassett said Sunday the Trump administration is not targeting Medicare in its sweeping budget proposal, but signaled the administration would be open to changes if senators uncover fraud or abuse as they look at the bill. "If somebody finds waste, fraud and abuse in Medicare, then of course we would look at it," Hassett said on "Face the Nation with Margaret Brennan." "But there have been a lot of false stories about Medicare being on the table, and it's totally not on the table." Senate Republicans this week are working on the House-passed budget bill, dubbed the "One Big Beautiful Bill" by President Trump, which includes deep tax cuts, border security measures, and changes to Medicaid and food assistance programs. Hassett on Sunday pushed back against the idea that Republicans are targeting Medicare for cuts. "That story that got out last week was covered as our intent to go after Medicare," Hassett said bluntly. "And it was just a big fake news story." National Economic Council director Kevin Hassett on "Face the Nation with Margaret Brennan," June 2, 2025. CBS News Asked whether the administration would revisit the Medicare provision if the Senate identifies abuse, Hassett said they would. "I've seen a massive amount of waste, fraud and abuse in Medicaid, and I've not been briefed on Medicare waste, fraud and abuse. But if they find something then, of course, we would look at it," he said. The nonpartisan Congressional Budget Office estimated earlier this week that the bill will add $2.4 trillion to the national debt over the next decade. Sen. Thom Tillis told Charlotte's WCNC on Thursday that he supports legislation that would address waste in the Medicare Advantage Program. This addition, he said, would not touch beneficiaries but would focus on "eliminating waste, fraud, and abuse of the Medicare Advantage program, including costly government overpayments to insurance companies." To pay for some of Mr. Trump's tax reforms, such as extending his 2017 tax cuts and eliminating tax on tips, there are cuts to several programs. Republicans have insisted they are not cutting Medicaid, and reductions in the low-income entitlement program have become one of the most charged parts of the bill. In a closed-door session with members of the Republican conference days before the bill's passage, sources in the room told CBS News Mr. Trump said, "Don't f*** around with Medicaid." House Republicans passed the bill late last month on a 215–214 vote, sending it to the Senate where GOP leaders are weighing revisions to secure enough votes under budget reconciliation rules. "What we want to see done now is we want the Senate to pass the bill, and then we want the House and Senate to work out their differences," Hassett said. "So right now, the Senate has to get the votes they need to pass the bill, and we're supporting them in that process." Some Republican senators, including Susan Collins of Maine, Lisa Murkowski of Alaska, and Josh Hawley of Missouri, have voiced concerns about Medicaid provisions in the bill, particularly new monthly premium requirements for low-income recipients. Their opposition highlights ongoing uncertainty as Senate GOP leaders work to secure enough votes. The bill can't afford to lose more than four votes in the Senate, granted that all Democrats vote against it. Hawley has called the Medicaid work requirements "both morally wrong and politically suicidal." When asked about Hawley's concerns, Hassett said, "I'd have to go see what he has and talk to him about it. And I also would want to talk to the president about the specific matter. So I can't speak to that one." The administration has repeatedly argued that failure to pass the legislation could hurt the broader economy. "If we don't pass this bill, then we lose 6 to 7 million jobs and 4% GDP," Hassett said Sunday. "If we create the jobs that we have in the bill, then we're going to create a heck of a lot more insurance than what we're talking about in waste, fraud and abuse." Senate Republicans are expected to release their version of the bill in the coming days. If there are significant changes, it will then have to go back to the House for final passage before landing on Mr. Trump's desk.
